Method of epitope discovery

Details Method of epitope discovery Method of epitope discovery

2005-03-01

2005-03-01

Nolan, Patrick J. (Department: 1644)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving viable micro-organism

C435S004000, C435S023000, C435S007800, C436S086000, C436S089000, C702S019000

Reexamination Certificate

active

06861234

ABSTRACT:
A method of epitope discovery comprising the step of selecting an epitope from a population of peptide fragments of an antigen associated with a target cell, wherein the fragments have a known or predicted affinity for a major histocompatibility complex class I receptor peptide binding cleft, wherein the epitope selected corresponds to a proteasome cleavage product of the target cell.

REFERENCES:
patent: 4439199 (1984-03-01), Amkraut et al.
patent: 4683199 (1987-07-01), Palladino
patent: 4937190 (1990-06-01), Palmenberg et al.
patent: 5093242 (1992-03-01), Bachmair et al.
patent: 5132213 (1992-07-01), Bachmair et al.
patent: 5149783 (1992-09-01), Sommergruber et al.
patent: 5168062 (1992-12-01), Stinski
patent: 5258294 (1993-11-01), Boyle et al.
patent: 5385839 (1995-01-01), Stinski
patent: 5478556 (1995-12-01), Elliott et al.
patent: 5496360 (1996-03-01), Hoffman et al.
patent: 5496721 (1996-03-01), Bachmair et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5646017 (1997-07-01), Bachmair et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5698396 (1997-12-01), Pfreundschuh
patent: 5733548 (1998-03-01), Restifo et al.
patent: 5744316 (1998-04-01), Lethe et al.
patent: 5747269 (1998-05-01), Rammensee et al.
patent: 5759551 (1998-06-01), Ladd et al.
patent: 5844075 (1998-12-01), Kawakami et al.
patent: 5846540 (1998-12-01), Restifo et al.
patent: 5847097 (1998-12-01), Bachmair et al.
patent: 5856187 (1999-01-01), Restifo et al.
patent: 5869453 (1999-02-01), Moss et al.
patent: 5880103 (1999-03-01), Urban et al.
patent: 5912167 (1999-06-01), Palmenberg et al.
patent: 5925565 (1999-07-01), Berlioz et al.
patent: 5962428 (1999-10-01), Carrano et al.
patent: 5989565 (1999-11-01), Storkus et al.
patent: 5993828 (1999-11-01), Morton
patent: 5994523 (1999-11-01), Kawakami et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6060273 (2000-05-01), Dirks et al.
patent: 6287569 (2001-09-01), Kipps et al.
patent: 20030186355 (2003-10-01), Ossendorp et al.
patent: 2147863 (1994-05-01), None
patent: 9303175 (1995-04-01), None
patent: 1 118 860 (2001-07-01), None
patent: 74899 (1997-08-01), None
patent: 9221033 (1992-11-01), None
patent: WO9601429 (1996-01-01), None
patent: WO 9640209 (1996-12-01), None
patent: WO9734613 (1997-09-01), None
patent: WO 9741440 (1997-11-01), None
patent: WO 9741440 (1997-11-01), None
patent: WO 9813489 (1998-04-01), None
patent: WO 9814464 (1998-04-01), None
patent: WO 9924596 (1999-05-01), None
patent: WO 01090197 (2001-11-01), None
US 6,008,200, 12/1999, Krieg (withdrawn)
Shimbara et al., Genes to Cells vol. 2, pp. 785-800, 1997.*
Groettrup et al. JBC vol. 270: pp. 23808-23815, 1995.*
Ausubel, Frederick M. et al.,Short Protocols in Molecular Biology, Third Edition, Unit 11.2, pp. 11-5—11-16 (1997).
Carulli, John P. et al., “High Throughput Analysis of Differential Gene Expression”,Journal of Cellular Biochemistry Supplements, vol. 30/31:286-296 (1998).
Falk, Kirsten et al., “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules”, Nature, vol. 351, pp. 290-295 (May 23, 1991).
Kawakami, Yutaka, et al. “Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor”, Proc. Natl. Acad. Sci. USA, vol. 91, pp. 3515-3519 (Apr. 1994).
NCBI Blast Accession No. NO_005502, 2 pages.
Türeci, Özlem, et al. “Identification of a meiosis-specific protein as a member of the class of cancer / testis antigens”, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 5211-5216 (Apr. 1998).
Williams, Kevin P., et al., “Isolation of a Membrane-Associated Cathespin D-like Enzyme from a Model Antigen Presenting Cell, A20, and its ability to Generate Antigenic Fragments from a Protein Antigen in a Cell-Free System”, vol. 305, No. 2pp. 298-306 (Sep. 1993).
International Search Report re International Application No. PCT/US02/36098 Date of Mailing of International Search Report: Jan. 15, 2004.
Van Den Eynde, et al. “Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome,” Current Opinion in Immunology, vol. 13, pp. 147-153 (2001).
International Search Report re International Application No. PCT/US03/26231 Date of Mailing of International Search Report: Dec. 2, 2003.
International Search Report re International Application No. PCT/US02/35582 Date of Mailing of International Search Report: Nov. 14, 2003.
Elke Jäger et al., “Identification of NY-ESO-1 Epitopes Presented by Human Histocompatibility Antigen (HLA)-DRB4*0101-0103 and Recognized by CD4+T Lymphocytes of Patients with NY-ESO-1-expressing Melanoma”J. Exp. Med, vol. 191, No 4, pp. 625-630 (Feb. 21, 2000).
Steven A. Rosenberg, “A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes”, Science, vol. 233, pp. 1318-1321 (Sep. 19,1986).
Naoki Shimbara et al., “Contribution of Proline Residue for Efficient Production of MHC Class I Ligands by Proteasomes,” The Journal of Biological Chemistry, vol. 273, No. 36, pp. 23062-23071. 1998.
Altuvia, et al., “A Structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets,”Human Immunology, 58: 1-11 (1997).
Ayyoub, et al., “Lack of tumor recognition by hTERT peptide 540-548-specific CD8+T cells from melanoma patients reveals inefficient antigen processing,”Eur. J. Immunol., 31:2642-2651 (2001).
Bettinotti, et al, “Stringent Allele/Epitope Requirements for MART-1/Melan A Immunodominance: Implications for Peptide-Based Immunotherapy,”J. Immunol., 161:877-889 (1998).
Brown, et al., “Structural and serological simularity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes,”Nature, 353:355-357 (1991).
Butterfield, et al., “Generation of Melanoma-Specific Cytotoxic T Lymphocytes by Dendritic Cells Tranduced with a MART-1 Adenovirus,”J. Immunol., 161:5607-5613 (1998).
Chattergoon, et al., “Genetic Immunization: a new era in vaccines and immune therapeutics,”FASEB J., 11:753-763 (1997).
Chaux, et al., “Identification of Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by In Vitro Stimulation with Dendritic Cells Transduced with MAGE-A1, ”The Journal of Immunology, 163: 2928-2936 (1999).
Davis, H. L., “Plasmid DNA expression systems for the purpose of immunization,”Current Opinion in Biotechnology, 8:635-640 (1997).
Dean, D. A. et al., “Sequence requirements for plasmid nuclear import,”Experimental Cell Research, 253:713-722 (1999).
Dick, et al., “Proteolytic Processing of Ovalbumin and β-galactosidase by the Proteasome to Yield Antigenic Peptides,”J. Immunology, 152:3884-3894 (1994).
Farrar, et al., “The molecular cell biology of interferon-γ and its receptor,”Annu. Rev. Immunol.11:571-611 (1993).
Fiette, et al., “Theiler's virus infection of 129Sv mice that lack the interferon α/β or interferon γ receptors,”J. Exp. Med., 181:2069-2076 (1995).
Gale, Jr., et al, “Evidence that Hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein,”Virology, 230:217-227 (1997).
Glynne, et al. , “A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC,”Nature, 353:357-360 (1991).
Gulukota, et al., “Two Complementary methods for predicting peptides binding major histocompatibility complex molecules,”J. Mol. Biol., 267: 1258-1267 (1997).
Gurunathan, S. et al., “DNA vaccines: a key for inducing long-term cellular immunity,”Current Opinion in Immunology, 12:422-447 (2000).
Heim, et al., “Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway,

Affiliated with

Also associated with

Rating

Method of epitope discovery does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of epitope discovery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of epitope discovery will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3435436